tlooto
Sign up
MedicineBiology

Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)

A. M. Bergman, H. Pinedo, G. Peters

2002.2.1DRUG RESISTANCE UPDATES

DOI: 10.1016/s1368-7646(02)00002-x

tlooto Summary

The pre-clinical mechanisms of acquired and inherent resistance to the fluorinated deoxycytidine analog gemcitabine (2',2'-difluorodeoxycyte, dFdC, Gemzar((R), which has proven activity in non-small cell lung carcinoma, pancreatic and bladder cancer are summarized.

Abstract

Abstract is not available.

Citation format

BERGMAN, A. M.; PINEDO, H.; PETERS, G. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). DRUG RESISTANCE UPDATES, 2002, 5: 19–33.